Literature DB >> 9108081

In vitro restoration of T cell responses in tuberculosis and augmentation of monocyte effector function against Mycobacterium tuberculosis by natural inhibitors of transforming growth factor beta.

C S Hirsch1, J J Ellner, R Blinkhorn, Z Toossi.   

Abstract

We examined the capacity of the naturally occurring inhibitors of transforming growth factor beta (TGF-beta), decorin and latency associated peptide (LAP), to reverse depressed T cell functions in peripheral blood mononuclear cells (PBMCs) from patients with pulmonary tuberculosis (TB) in vitro and to counteract the suppressive properties of TGF-beta on mycobacterial replication in blood monocytes (MN) in vitro. T cell blastogenesis in response to purified protein derivative (PPD) in PBMCs of TB patients that were cocultured with decorin or LAP reached levels comparable to those observed in healthy tuberculin-responsive control subjects. Decorin and LAP were as effective as neutralizing antibody to TGF-beta in correcting depressed T cell proliferation. Coculture of PBMCs from healthy PPD reactive individuals with neutralizing antibody to TGF-beta, decorin, or LAP did not affect T cell blastogenesis. Levels of interferon-gamma in cultures of PPD-stimulated PBMCs from patients with TB increased by more than 2-fold in the presence of maximal concentrations of either of the inhibitors of TGF-beta, whereas TGF-beta immunoreactivity declined to background levels. Coculture with optimal concentrations of decorin or LAP also led to reductions in mycobacterial growth in MN infected with Mycobacterium tuberculosis (MTB) in vitro by 51% and 62%, respectively, when compared with cells left untreated. In parallel, levels of immunoreactive TGF-beta in MTB-infected MN cultures containing decorin or LAP decreased to background levels. These data indicate that the naturally occurring inhibitors of TGF-beta, decorin and LAP, efficiently abrogate the suppressive effects of TGF-beta in PBMCs of TB patients and in MN infected with MTB in vitro. Therefore, these agents may be considered as adjuncts to antituberculous chemotherapy, and may be particularly useful in treatment of TB that is unresponsive to conventional chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9108081      PMCID: PMC20544          DOI: 10.1073/pnas.94.8.3926

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

Review 1.  Small proteoglycans.

Authors:  H Kresse; H Hausser; E Schönherr
Journal:  Experientia       Date:  1993-05-15

2.  Induction of transforming growth factor beta 1 by purified protein derivative of Mycobacterium tuberculosis.

Authors:  Z Toossi; T G Young; L E Averill; B D Hamilton; H Shiratsuchi; J J Ellner
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

3.  Distribution of extracellular matrices, matrix receptors, and transforming growth factor-beta 1 in human and experimental lung granulomatous inflammation.

Authors:  J Roman; Y J Jeon; A Gal; R L Perez
Journal:  Am J Med Sci       Date:  1995-03       Impact factor: 2.378

4.  Enhancement of intracellular growth of Mycobacterium tuberculosis in human monocytes by transforming growth factor-beta 1.

Authors:  C S Hirsch; T Yoneda; L Averill; J J Ellner; Z Toossi
Journal:  J Infect Dis       Date:  1994-11       Impact factor: 5.226

5.  Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis.

Authors:  A Barral; M Barral-Netto; E C Yong; C E Brownell; D R Twardzik; S G Reed
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

6.  Enhanced production of TGF-beta by blood monocytes from patients with active tuberculosis and presence of TGF-beta in tuberculous granulomatous lung lesions.

Authors:  Z Toossi; P Gogate; H Shiratsuchi; T Young; J J Ellner
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

7.  Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease.

Authors:  W A Border; N A Noble; T Yamamoto; J R Harper; Y u Yamaguchi; M D Pierschbacher; E Ruoslahti
Journal:  Nature       Date:  1992-11-26       Impact factor: 49.962

Review 8.  The emerging role of transforming growth factor-beta in kidney diseases.

Authors:  K Sharma; F N Ziyadeh
Journal:  Am J Physiol       Date:  1994-06

Review 9.  Transforming growth factor beta: a matter of life and death.

Authors:  N L McCartney-Francis; S M Wahl
Journal:  J Leukoc Biol       Date:  1994-03       Impact factor: 4.962

10.  An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection.

Authors:  J L Flynn; J Chan; K J Triebold; D K Dalton; T A Stewart; B R Bloom
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more
  46 in total

1.  Latency-associated peptide of transforming growth factor beta enhances mycobacteriocidal immunity in the lung during Mycobacterium bovis BCG infection in C57BL/6 mice.

Authors:  K A Wilkinson; T D Martin; S M Reba; H Aung; R W Redline; W H Boom; Z Toossi; S A Fulton
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

Review 2.  Tuberculosis: latency and reactivation.

Authors:  J L Flynn; J Chan
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

3.  A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis.

Authors:  R Hernández-Pando; H Orozco-Esteves; H A Maldonado; D Aguilar-León; M M Vilchis-Landeros; D A Mata-Espinosa; V Mendoza; F López-Casillas
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

4.  Mycobacterium bovis BCG-infected mice are more susceptible to staphylococcal enterotoxin B-mediated toxic shock than uninfected mice despite reduced in vitro splenocyte responses to superantigens.

Authors:  João A Pedras-Vasconcelos; Yvan Chapdelaine; Renu Dudani; Henk van Faassen; Dean K Smith; Subash Sad
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

Review 5.  Immunoregulation in TB: observations and implications.

Authors:  Jerrold J Ellner
Journal:  Clin Transl Sci       Date:  2010-02       Impact factor: 4.689

6.  Invasive candidiasis stimulates hepatocyte and monocyte production of active transforming growth factor beta.

Authors:  J J Letterio; T Lehrnbecher; G Pollack; T J Walsh; S J Chanock
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

7.  IFN-gamma induces the erosion of preexisting CD8 T cell memory during infection with a heterologous intracellular bacterium.

Authors:  Renu Dudani; Kaja Murali-Krishna; Lakshmi Krishnan; Subash Sad
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

8.  In vitro levels of interleukin 10 (IL-10) and IL-12 in response to a recombinant 32-kilodalton antigen of Mycobacterium bovis BCG after treatment for tuberculosis.

Authors:  V Hari Sai Priya; B Anuradha; Suman Latha Gaddam; Seyed E Hasnain; K J R Murthy; Vijaya Lakshmi Valluri
Journal:  Clin Vaccine Immunol       Date:  2008-11-05

9.  Intestinal helminth co-infection has a negative impact on both anti-Mycobacterium tuberculosis immunity and clinical response to tuberculosis therapy.

Authors:  T Resende Co; C S Hirsch; Z Toossi; R Dietze; R Ribeiro-Rodrigues
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

10.  Application of molecular, microbiological, and immunological tests for the diagnosis of bone and joint tuberculosis.

Authors:  Yinghua Tang; Lianli Yin; Shifu Tang; Hongyu Zhang; Jihui Lan
Journal:  J Clin Lab Anal       Date:  2017-05-22       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.